Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
crispr
5
×
life sciences
national
5
×
national blog main
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
cancer
crispr therapeutics
eli lilly
fda
gene therapy
glaxosmithkline
novartis
biogen
cancer immunotherapy
celgene
clinical trials
deals
What
new
5
×
bio
roundup
crispr
cancer
known
remains
allogene
approval
bails
biogen’s
biopharma
biopharmaceutical
brand
bridgebio
capital
car
cas
cells
companies
congress
congressional
convo
defect
develop
diversity
drive
drug
drugs
earlier
edited
editing
emerges
executives
failures
fears
feud
firm
flag
gene
Language
unset
Current search:
national
×
new
×
crispr
×
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells